JK06 Biparatopic 5T4-Targeted MMAE ADC: Overcoming the Challenges of a Difficult Target Through Rational Design

• Reviewing target and molecule design rationale for a first-in-class quadrivalent, biparatopic ADC that selectively targets 5T4 with an MMAE payload
• Outlining safety data and comparison with historical MMAE ADC safety data
• Sharing efficacy data in solid tumours, NSCLC and breast cancer

Speakers:

Samuel Murphy

Vice President & Head of International Business Development

Salubris Biotherapeutics Inc.